Barely Significant
← all excerpts

Fulvestrant in advanced breast cancer: evidence to date and place in therapy.

Ther Adv Med Oncol · 2017 · PMC5502950 · PMID 28717399

Europe PMCDOI
1
hedged sentence
0.0490
closest p · 1.0× alpha
0.0490
boldest claim

The sentences

marginally significantp = 0.049actually significant
The SWOG 0226 phase III trial showed a significant improvement in PFS (15 versus 13.5 months; p = 0.007) and marginally significant OS (47.7 months versus 41.3 months; p = 0.049) in favour of fulvestrant plus anastrozole, despite the use of a dose of fulvestrant below the current standard.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.